1.
Rabinowits G, Homsi J, Nikanjam M, Gentry R, Strasswimmer J, Venna S, Migden M, Chandra S, Ruiz E, Zhang H, McGinniss J, Seluzhytsky A, Desai J. Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma. J of Skin [Internet]. 2020Oct.27 [cited 2024Jul.15];4(6):s125. Available from: https://jofskin.org/index.php/skin/article/view/1098